Regulation of cancer cell migration and bone metastasis by RANKL.
The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Abstract
Bone metastases are a frequent complication of many cancers that result in severe disease burden and pain. Since the late nineteenth century, it has been thought that the microenvironment of the local host tissue actively participates in the propensity of certain cancers to metastasize to specific organs, and that bone provides an especially fertile 'soil'. In the case of breast cancers, the local chemokine milieu is now emerging as an explanation for why these tumours preferentially metastasize to certain organs. However, as the inhibition of chemokine receptors in vivo only partially blocks metastatic behaviour, other factors must exist that regulate the preferential metastasis of breast cancer cells. Here we show that the cytokine RANKL (receptor activator of NF-kappaB ligand) triggers migration of human epithelial cancer cells and melanoma cells that express the receptor RANK. RANK is expressed on cancer cell lines and breast cancer cells in patients. In a mouse model of melanoma metastasis, in vivo neutralization of RANKL by osteoprotegerin results in complete protection from paralysis and a marked reduction in tumour burden in bones but not in other organs. Our data show that local differentiation factors such as RANKL have an important role in cell migration and the tissue-specific metastatic behaviour of cancer cells.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“MDA-231 cells and other human breast cancer cells have been shown to express RANK (101, 336)”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [336]
Citations
Cites
Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation.
Lacey, D. L., Timms, E., Tan, H.-L., Kelley, M. J., Dunstan, C. R., Burgess, T., Elliott, R., Colombero, A., Elliott, G., Scully, S., et al. (1998) · Cell · doi:10.1016/s0092-8674(00)81569-x · Cited by 5,439
Self-citationInvolvement of chemokine receptors in breast cancer metastasis
Müller, A., Homey, B., Soto, H., Ge, N., Catron, D., Buchanan, M. E., McClanahan, T., Murphy, E., Yuan, W., Wagner, S. N., et al. (2001) · Nature · doi:10.1038/35065016 · Cited by 5,340
The distribution of secondary growths in cancer of the breast.
Paget, S. (1889) · The Lancet · doi:10.1016/s0140-6736(00)49915-0 · Cited by 5,277
Bone Resorption by Osteoclasts
Teitelbaum, S. L. (2000) · Science · doi:10.1126/science.289.5484.1504 · Cited by 3,962
Dissemination and growth of cancer cells in metastatic sites
Chambers, A. F., Groom, A. C., & MacDonald, I. C. (2002) · Nature Reviews Cancer · doi:10.1038/nrc865 · Cited by 3,911
OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph node organogenesis.
Kong, Y.-Y., Yoshida, H., Sarosi, I., Tan, H.-L., Timms, E., Capparelli, C., Morony, S., Oliveira-dos-Santos, A. J., Van, G., Itie, A., et al. (1999) · Nature · doi:10.1038/16852 · Cited by 3,351
Self-citationMetastasis to bone: causes, consequences and therapeutic opportunities
Mundy, G. R. (2002) · Nature Reviews Cancer · doi:10.1038/nrc867 · Cited by 2,777
The microenvironment of the tumour–host interface
Liotta, L. A., & Kohn, E. C. (2001) · Nature · doi:10.1038/35077241 · Cited by 2,310
A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function.
Anderson, D. M., Maraskovsky, E., Billingsley, W. L., Dougall, W. C., Tometsko, M. E., Roux, E. R., Teepe, M. C., DuBose, R. F., Cosman, D., & Galibert, L. (1997) · Nature · doi:10.1038/36593 · Cited by 2,290
Fata, J. E., Kong, Y.-Y., Li, J., Sasaki, T., Irie-Sasaki, J., Moorehead, R. A., Elliott, R., Scully, S., Voura, E. B., Lacey, D. L., et al. (2000) · Cell · doi:10.1016/s0092-8674(00)00103-3 · Cited by 756
Self-citation
Cited by
Items 601–700 of 864
Brook, N., Dharmarajan, A., Chan, A., & Dass, C. R. (2023) · Journal of Pharmacy and Pharmacology · doi:10.1093/jpp/rgad039 · Cited by 5
Deligiorgi, M. V., Panayiotidis, M. I., & Trafalis, D. T. (2020) · Journal of B.U.ON. : official journal of the Balkan Union of Oncology · Cited by 5
Signaling Pathways Underlying Bone Metastasis: Hypoxia Signaling in Bone Metastasis and Beyond
Devignes, C.-S., Aslan, Y., & Provot, S. (2018) · Current Molecular Biology Reports · doi:10.1007/s40610-018-0090-1 · Cited by 4
Denosumab: First Data and Ongoing Studies on the Prevention of Bone Metastases
von Moos, R., & Skácel, T. (2012) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-642-21892-7_9 · Cited by 4
Campbell‐Baird, C., Lipton, A., Sarkeshik, M., Ma, H., & Jun, S. (2010) · Community Oncology · doi:10.1016/s1548-5315(11)70560-5 · Cited by 4
Osteoclast-Like Giant Cells in Malignant Melanoma: Unintentional Accident or Strategic Recruitment?
Li, X., Savory, S., Vandergriff, T. W., & Glass, D. A. (2017) · American Journal of Dermatopathology · doi:10.1097/dad.0000000000000860 · Cited by 4
Maeda, T., Kitamura, S., & Yanagi, T. (2020) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.16714 · Cited by 4
Furukawa, K., Haruki, K., Taniai, T., Yanagaki, M., Tsunematsu, M., Tanji, Y., Ishizaki, S., Shirai, Y., Onda, S., & Ikegami, T. (2023) · Cancers · doi:10.3390/cancers15235513 · Cited by 4
“The evaluation of preoperative OVF might be a useful prognostic indicator for patients with CRLM.”
BackgroundTobin, G., Kalupahana, R. S., & Kulk, M. (2013) · InTech eBooks · doi:10.5772/55794 · Cited by 4
“The expression of both receptor activator of NF-κB (RANK) and RANK ligand (RANKL) have been observed in primary breast cancers in humans and breast cancer cell lines [315].”
BackgroundPremnath, P., Tan, B., & Venkatakrishnan, K. (2015) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2015.10.007 · Cited by 4
RANK/RANKL pathway in cancer: Biological activity beyond bone?
Pantano, F., Clézardin, P., & Santini, D. (2012) · Journal of bone oncology · doi:10.1016/j.jbo.2012.11.001 · Cited by 4
“Moreover, RANKL inhibition has been demonstrated to reduce bone lesions and tumour burden in vivo in melanoma model of bone metastasis [6].”
BackgroundPharmacological mechanisms of therapeutics
Tsourdi, E. A., Ominsky, M. S., Rachner, T. D., Hofbauer, L. C., & Kostenuik, P. J. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-814841-9.00073-7 · Cited by 4
Targeted Therapies in Early-Stage Breast Cancer: Achievements and Promises
Sledge, G. W., Jotwani, A. C., & Mina, L. A. (2010) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2010.04.005 · Cited by 4
“Binding of RANKL to the osteoclasts stimulate increased bone resorption and the release of other growth factors that trigger a cycle of bone destruction and tumor cell proliferation, in addition to the migration of tumor cells to the bone.(45,46) Denosumab is a fully human monoclonal antibody that specifically inhibit…”
BackgroundZhang, H., Li, Z.-J., Fu, X., Ma, J., & Ma, X. (2013) · Archives of Medical Research · doi:10.1016/j.arcmed.2012.11.006 · Cited by 4
CLINICOPATHOLOGICAL EVALUATION OF BONE METASTASIS IN GASTRIC CANCER PATIENTS
Yokoyama, T., Watanabe, A., Migita, K., Nakagawa, K., Inoue, T., Mukogawa, T., Ohyama, T., & Ishikawa, H. (2009) · Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association) · doi:10.3919/jjsa.70.656 · Cited by 4
The stem cell niche and bone metastasis
Strewler, G. J. (2006) · BoneKEy-Osteovision · doi:10.1138/20060211 · Cited by 4
“RANK is a functional signaling molecule in breast and prostate carcinoma and could transmit survival signals to tumor cells from osteoblasts that express RANK ligand (56-58).”
BackgroundKawakami, M., Yasuda, H., Nishida, D., Katakura, A., & Mizoguchi, T. (2021) · Journal of Oral Biosciences · doi:10.1016/j.job.2021.01.009 · Cited by 3
Gomes, I., Martelo, M., Vilela, R. D., Jiménez, M., Trinidad, E. M., Miragaya, J. G., González‐Suárez, E., Martins, É., Torres, S. S., Corredeira, P., et al. (2025) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-24-1158 · Cited by 3
Sánchez‐Céspedes, R., Millán, Y., Guil‐Luna, S., García-Macías, J., Maniscalco, L., Iussich, S., Maria, R. D., & Mulas, J. M. D. L. (2017) · Journal of Veterinary Diagnostic Investigation · doi:10.1177/1040638717735867 · Cited by 3
BMP Signaling Is a Prognostic Marker in Patients With Colorectal Cancer and Associates With Frailty
Sawata, S., Shimizu, S., Matsumi, Y., Kono, Y., Kihara, K., Yamamoto, M., Sakamoto, T., Umekita, Y., & Fujiwara, Y. (2024) · Cancer Diagnosis & Prognosis · doi:10.21873/cdp.10341 · Cited by 3
Remodelling of the Extracellular Matrix: Implications for Cancer
Cox, T. R., & Erler, J. T. (2013) · Humana Press eBooks · doi:10.1007/978-1-62703-634-4_4 · Cited by 3
Pourquoi certains cancers métastasent-ils préférentiellement à l’os ?
Clézardin, P. (2012) · ONCOLOGIE · doi:10.1007/s10269-011-2105-x · Cited by 3
Okamoto, K., & Takayanagi, H. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-804182-6.00016-2 · Cited by 3
Wang, H., Hu, A., Liang, Y., Wang, K., Zhou, X., & Dong, J. (2020) · Annals of Translational Medicine · doi:10.21037/atm-20-7046 · Cited by 3
“In the past few decades, researchers have determined that SM of lung cancer is a complex biologic process characterized by various molecular abnormalities, such as the axis of stromal derived factor-1/chemokine (C-X-C motif) receptor 4 (CXCR4) (23), and the activation of the receptor activator of the NF-κB (RANK) liga…”
BackgroundDepression and anxiety in recurrent giant cell tumor of bone
Popescu, M. J., Stoicea, M. C., Marinescu, I. P., Cismasiu, R. S., Stovicek, P. O., Tudose, C., & Ciobanu, A. M. (2021) · Romanian Journal of Morphology and Embryology · doi:10.47162/rjme.61.4.08 · Cited by 3
“Interestingly, in conditions of depression and stress, there is an amplification of TNFα, and the RANK– RANK-L–osteoprotegerin cytokine system, considered TNF-related proteins, is involved in bone tumors as well as breast and prostate cancer [68, 69].”
BackgroundProgesterone and not estrogens or androgens causes breast cancer
Bennink, H. J. T. C., & Stanczyk, F. Z. (2024) · Climacteric · doi:10.1080/13697137.2023.2292073 · Cited by 3
Early Bone Metastasis-Associated Molecular and Cellular Events
Clézardin, P. (2010) · Elsevier eBooks · doi:10.1016/b978-0-12-374895-9.00003-7 · Cited by 3
Breast Cancer Metastases to Bone: Role of the Microenvironment
Jenna, E., & Светлана, В. (2011) · InTech eBooks · doi:10.5772/21741 · Cited by 3
“Another pertinent means of cancer cell migration towards bone relies on the cancer cell expression of RANK (96), which mediates directional migration of breast, melanoma and prostate cancer cells towards RANKL, produced in bone by osteoblasts (97,98).”
BackgroundBone and Immune Cell Interactions
Boyce, B. F. (2013) · Wiley eBooks · doi:10.1002/9781118453926.ch124 · Cited by 3
Dougall, W. C. (2010) · Elsevier eBooks · doi:10.1016/b978-0-12-374895-9.00032-3 · Cited by 3
High hopes for RANKL: will the mouse model live up to its promise?
Tanos, T., & Brisken, C. (2011) · Breast Cancer Research · doi:10.1186/bcr2805 · Cited by 3
“Analysis of RANK- and RANKL-defi cient mice pointed to a role for this pathway in the mammary gland during pregnancy [5] and in mammary carcinoma metastasis to the bone [6].”
Tumor-Bone Cell Interactions in Bone Metastases
Fournier, P. G. J., Dunn, L. K., Clines, G. A., & Guise, T. A. (2010) · Elsevier eBooks · doi:10.1016/b978-0-12-374895-9.00002-5 · Cited by 3
Metastases to the Pelvis: Algorithm of Treatment
Angelini, A., Trovarelli, G., & Ruggieri, P. (2018) · Springer eBooks · doi:10.1007/978-3-319-73485-9_10 · Cited by 3
Hai, L., Szwarc, M. M., Lonard, D. M., Rajapakshe, K., Perera, D. N., Coarfa, C., Ittmann, M., Fernandez‐Valdivia, R., & Lydon, J. P. (2019) · Cytokine · doi:10.1016/j.cyto.2019.154745 · Cited by 3
Deligiorgi, M. V., Panayiotidis, M. I., & Trafalis, D. T. (2020) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2020.1839416 · Cited by 3
“to act as a ‘soil’ factor facilitating the migration of cancer cells [31].”
BackgroundThe RANKL/RANK system in female reproductive organ tumors: A preclinical and clinical overview
Miralles, A. M., González, V. M., Smith-Ballester, S., Iglesias-Miguel, V., & Cano, A. (2021) · Advances in Clinical and Experimental Medicine · doi:10.17219/acem/140422 · Cited by 3
Prospects of adjuvant RANKL inhibition in breast cancer?
Rachner, T. D., Wimberger, P., & Hofbauer, L. C. (2015) · Cell Death and Disease · doi:10.1038/cddis.2015.332 · Cited by 3
Rondeau, E. (2021) · theses.fr (ABES) · doi:10.70675/6e037beazf15ez47c5z9490z55191ed1ca1f · Cited by 3
Haruki, K., Furukawa, K., Akaoka, M., Tsunematsu, M., Matsumoto, M., Taniai, T., Shirai, Y., Onda, S., Hamura, R., & Ikegami, T. (2025) · Annals of Gastroenterological Surgery · doi:10.1002/ags3.12912 · Cited by 2
Aiolfi, A., Bona, D., Bonitta, G., Wang, Q., Albano, D., Bonavina, G., Caruso, R., Banfi, G., Sconfienza, L. M., & Bonavina, L. (2025) · Annals of Surgical Oncology · doi:10.1245/s10434-025-18956-5 · Cited by 2
Unveiling the Rare: A Case of Renal Cell Carcinoma Acrometastasis
Ferraris, C. E., Ishizuka, M., & Schwartz, G. (2024) · Cureus · doi:10.7759/cureus.73612 · Cited by 2
Osteoimmunology: the effect of inflammation on bone
Nakashima, T., & Takayanagi, H. (2011) · Inflammation and Regeneration · doi:10.2492/inflammregen.31.404 · Cited by 2
Self-citationPeters, S., Letovanec, I., Mauer, M. E. L., Dafni, U. G., Ejedepang, D., Biernat, W., Bubendorf, L., Warth, A., Pokharel, S., Reinmuth, N., et al. (2022) · Lung Cancer · doi:10.1016/j.lungcan.2022.12.004 · Cited by 2
Giorello, M. B., Borzone, F. R., Mora, M. F., Padin, M. D. R., Wernicke, A., Labovsky, V., & Chasseing, N. A. (2024) · Cancer Biomarkers · doi:10.3233/cbm-230523 · Cited by 2
“Studies have highlighted the proliferative effect induced by the interaction between RANKL and RANK in breast epithelial cells, suggesting involvement in the initiation and progression of breast cancer [14,15,16,17,18,19].”
BackgroundInfluentialEffects of anti-RANKL and anti-PD-1 antibodies on cancer-induced osteolysis in mice
Chao, P.-C., Karakawa, A., Hosonuma, M., Azetsu, Y., Kamikawa, S., Oshio, A., Chatani, M., Shirota, T., & Takami, M. (2025) · Journal of Oral Biosciences · doi:10.1016/j.job.2025.100682 · Cited by 2
Gong, B., Guo, Y., Wan, Q., Lou, J., Li, Y., Xiong, T., Mo, P., Chen, Y., Liu, X., Wu, Z., et al. (2025) · MedComm · doi:10.1002/mco2.70398 · Cited by 2
“Cytokines secreted by tumor cells could stimulate osteoclasts and subsequently activate the NF-κ B (RANK)/RANK ligand (RANKL) pathway, which is related to the effectiveness of checkpoint blockade in cancer treatment [17, 18].”
Renaud, A., Vieillard, M.-H., Aubert, S., Gauthier, H. K., Ceugnart, L., & Cotten, A. (2013) · Elsevier eBooks · doi:10.1016/b978-2-294-71924-0.00018-8 · Cited by 2
Animal Models of Malignant Primary Bone Tumors and Novel Therapeutic Approaches
Rousseau, J., Lamoureux, F., Picarda, G. G. A., Gouin, F., Trichet, V., & Rédiní, F. (2010) · Elsevier eBooks · doi:10.1016/b978-0-12-374895-9.00028-1 · Cited by 2
Knochenmetastasen: Neues zur Pathogenese und systemischen Therapie
Rachner, T. D., Jakob, F. J., & Hofbauer, L. C. (2016) · Der Internist · doi:10.1007/s00108-016-0076-0 · Cited by 2
ESCI award lecture: from a little mouse to rationale medicine for bone loss
Leibbrandt, A., & Penninger, J. M. (2009) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.2009.02215.x · Cited by 2
Self-citationRANK and RANKL of Bones, T Cells, and the Mammary Glands
Sigl, V., & Penninger, J. M. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-800571-2.00008-6 · Cited by 2
Self-citationRoyer, B. B.-L., & Blanchard, F. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-416721-6.00010-8 · Cited by 2
Regulation of Tumor Progression and Metastasis by Bone Marrow-Derived Microenvironments
Rayes, T. E., Gao, D., Altorki, N. K., Cox, T. R., Erler, J. T., & Mittal, V. (2017) · Springer eBooks · doi:10.1007/978-3-319-39147-2_13 · Cited by 2
Osteoidbildende Knochentumoren: Morphologie und aktuelle translationale Zellbiologie
Roessner, A., Schoeder, V., Smolle, M. A., & Haybäck, J. (2020) · Der Pathologe · doi:10.1007/s00292-020-00763-2 · Cited by 2
RANK und RANKL - Vom Knochen zum Mammakarzinom
Sigl, Schramek, D., & Penninger, J. M. (2012) · Journal für Kardiologie (Krause & Pachernegg GmbH) · Cited by 2
Self-citationThe Role of Rankl in Prostate Cancer Progression and Bone Metastasis
Chu, C.-Y. (2011) · Digital Archive @ GSU · doi:10.57709/3075362 · Cited by 2
Breast Cancer: Role of Planar, SPECT and PET in Imaging Bone Metastases
Hofman, M. S., & Hicks, R. J. (2012) · Springer eBooks · doi:10.1007/978-3-642-02400-9_26 · Cited by 1
Diken, M., Boegel, S., Grunwitz, C. R., Kranz, L. M., Reuter, K. C., van de Roemer, N., Vascotto, F., Vormehr, M., & Kreiter, S. (2014) · Human Vaccines & Immunotherapeutics · doi:10.4161/hv.29767 · Cited by 1
“Further benefit of this therapeutic approach may be expected for bone metastasis, as data indicate that the inhibition of RANKL results in reduced tumor burden in bone and abolishment of paralysis in a mouse model of melanoma metastasis.(102) Penninger also talked about the role of RING finger E3 ubiquitin-protein lig…”
BackgroundPathogénie des métastases osseuses
Clézardin, P. (2008) · Revue du Rhumatisme · doi:10.1016/j.rhum.2007.12.002 · Cited by 1
Akdağ, G., Doğan, A., Yildirim, S., Kınıkoğlu, O., Mokresh, M. E., Alomarı, O., Türkoğlu, E., Işık, D., Sürmeli, H., Başoğlu, T., et al. (2024) · Cureus · doi:10.7759/cureus.63362 · Cited by 1
“…there is a substantial body of pre-clinical evidence indicating that RANK signaling promotes the proliferation and metastatic progression of BC [4,18,19], there is still considerable debate as to whether the targeted inhibition of RANK signaling by denosumab treatment will confer clinical…”
BackgroundJiang, Z., Zhang, J., Qiu, Z., Li, Z., Zhang, L., & Zhu, Z. (2026) · International Journal of Surgery · doi:10.1097/js9.0000000000004694 · Cited by 1
“RANKL functions as a “soil factor” in bone metastasis by recruiting RANK-expressing prostate cancer cells to colonize bone tissue [ 33 ] .”
Hu, Z., Chen, Z., Liu, Y., Su, T., & Li, J. (2026) · Biomaterials · doi:10.1016/j.biomaterials.2026.124398 · Cited by 1
Liu, Q., Zhang, Y., Jernigan, D. L., & Fatatis, A. (2011) · Springer eBooks · doi:10.1007/978-94-007-2558-4_11 · Cited by 1
Mori, K., Ando, K., Lézot, F., & Heym, D. (2011) · InTech eBooks · doi:10.5772/20518 · Cited by 1
Can osteoclasts be excluded? (Reply)
Jones, D. H., Nakashima, T., Sanchez, O. H., Kozieradzki, I., Komarova, S. V., Sarosi, I., Morony, S., Rubin, E., Sarao, R., Hojilla, C. V., et al. (2007) · Nature · doi:10.1038/nature05658 · Cited by 1
Self-citationHilbe, W., Abacıoğlu, U., Aebersold, D. M., Bachouchi, M., Brodowicz, T., Gaafar, R. M., Holzer, G., Mohn-Staudner, A., Kalev, D. N., Kalinka‐Warzocha, E., et al. (2013) · memo - Magazine of European Medical Oncology · doi:10.1007/s12254-013-0088-6 · Cited by 1
“The direct antineoplastic effect of RANKL inhibition on lung cancer cells is thought to be based on apoptosis or antimigration activity [23].”
BackgroundA Study of Osteoprotegerin in Diabetic Patients as Indicator for Myocardial Infarction
Hussein, I. A., Ajam, I. K., & Al-jebory, A. H. M. K. (2014) · Al-Kufa University Journal for Biology · Cited by 1
Explanation of Metastasis by Homeostatic Inflammation
Maru, Y. (2021) · Springer eBooks · doi:10.1007/978-981-16-1757-7_15 · Cited by 1
Toxicity of Bone-Targeted Agents in Malignancy
Wilson, C., Taylor, F., & Coleman, R. E. (2012) · Springer eBooks · doi:10.1007/978-0-85729-787-7_16 · Cited by 1
RANKL: A soil factor for cancer metastasis to bone?
Andrews, N. A. (2006) · BoneKEy-Osteovision · doi:10.1138/20060209 · Cited by 1
Bisphosphonate and Denosumab Therapy: Fields of Application
Then, C., von Tresckow, E., Bartl, R., & Oduncu, F. S. (2014) · Springer eBooks · doi:10.1007/978-3-662-43733-9_2 · Cited by 1
“On the other hand, preclinical data from animal models of breast cancer and melanoma suggest a role of the RANKL-RANK signaling pathway in tumor genesis and metastasis [ 63 , 64 ], and limited data indicates that denosumab may reduce disease progression in prostate cancer patients [ 54 ].”
BackgroundOutflanking RANK with a Designer Antagonist Cytokine
Ou-Yang, C.-W., & Siegel, R. M. (2014) · Science Signaling · doi:10.1126/scisignal.2005674 · Cited by 1
“In mouse tumor models, bone destruction and the frequency of metastases is RANK-dependent (10).”
BackgroundA local basis for progesterone action during mammary tumorigenesis - no longer RANK and file
Petrie, W. K., & Hovey, R. C. (2011) · Breast Cancer Research · doi:10.1186/bcr2802 · Cited by 1
“Correspondingly, RANK is expressed by a number of breast cancer cell lines, primary breast tumors and local breast lymph node metastases [2], lending strong support to a role for RANK/RANKL in breast cancer progression and metastasis.”
BackgroundInvolvement of sympathetic nerves in bone metastasis
Elefteriou, F., & Campbell, P. J. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-416721-6.00049-2 · Cited by 1
Are we trumping bone disease in prostate cancer?
Slovin, S. F. (2011) · PubMed · Cited by 1
Denosumab: Renal Safety Evaluation
Malberti, F., & Foramitti, M. (2017) · Journal of Onco-Nephrology · doi:10.5301/jo-n.5000016 · Cited by 1
“The expression of RANKL in bone may contribute to the development of bone metastases by binding to its receptor on the surface of tumor cells (10).”
BackgroundBertolaso, P., Leroy, L., Gross‐Goupil, M., Aupée, O., Ravaud, A., Roubaud, G., Cazeau, A. L., & Moulec, S. L. (2017) · Bulletin du Cancer · doi:10.1016/j.bulcan.2017.06.011 · Cited by 1
Owen, S., Zabkiewicz, C., Ye, L., Sanders, A. J., Gong, C., & Jiang, W. G. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-981-10-6020-5_9 · Cited by 1
Novel targeted therapies of bone tumors and future directions
Heymann, D. (2012) · doi:10.2217/ebo.11.352 · Cited by 1
Chen, Y., Wang, Z., Liu, M., Wang, X., Zhang, L., & Gong, C. (2018) · Tropical Journal of Pharmaceutical Research · doi:10.4314/tjpr.v17i9.4 · Cited by 1
“Anticancer agents that supress the migration of cancer cells have been reported to be important, since they can efficiently inhibit the metastasis of cancer cells [19].”
BackgroundCancer, Hayflick limit and the Entscheidungsproblem
Skopec, R. (2017) · Global Vaccines and Immunology · doi:10.15761/gvi.1000127 · Cited by 1
Quantification of cancer cell migration with an integrated experimental-computational pipeline
Juarez, E. F., Garri, C., Ghaffarizadeh, A., Macklin, P., & Kani, K. (2018) · F1000Research · doi:10.12688/f1000research.15599.1 · Cited by 1
A Pillar-Free Diffusion Device for Studying Chemotaxis on Supported Lipid Bilayers
Hao, J., Zhao, W., Oh, J. M., & Shen, K. (2021) · Micromachines · doi:10.3390/mi12101254 · Cited by 1
Toxicity of Bone-Targeted Agents in Malignancy
Wilson, C., Taylor, F., & Coleman, R. E. (2018) · Springer eBooks · doi:10.1007/978-3-319-70253-7_17 · Cited by 1
Tridente, G. (2013) · Springer eBooks · doi:10.1007/978-88-470-5313-7_17 · Cited by 1
Meier, M. E., Hagelstein-Rotman, M., Majoor, B. C. J., Geels, R. E. S., Appelman‐Dijkstra, N. M., & Bravenboer, N. (2023) · Bone · doi:10.1016/j.bone.2023.116679 · Cited by 1
Masset, M. E. G., Canto, F. B., & Monteiro, A. C. (2025) · IntechOpen eBooks · doi:10.5772/intechopen.1010215 · Cited by 1
Роль системы RANK/RANKL/OPG в патогенезе первичных и метастатических опухолей костей
Kushlinskiy, N. E., & Timofeev, Y. A. (2023) · Nauchno-prakticheskii zhurnal «Patogenez» · Cited by 1
Lafantaisie-Favreau, C.-H. (2011) · PolyPublie (École Polytechnique de Montréal) · Cited by 1
Reyes, M. E. (2014) · Digital Commons-TMC (Texas Medical Center) · Cited by 1
Einfluss von GnRH Analoga auf die Metastasierung humaner Mammakarzinomzellen in vitro und in vivo
Schubert, A. (2010) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-411 · Cited by 1
RANKL: Targeting bone and cancer to treat skeletal complications of malignancy
Crook, M. K., & Guise, T. A. (2009) · IBMS BoneKEy · doi:10.1138/20090396 · Cited by 1
“Because OPG was effective in a system thought to be devoid of osteoclast activation, the authors concluded that the decrease in bone metastases was caused by inhibition of RANKL-mediated homing of cancer cells to bone and not by increased bone turnover (36).”
BackgroundDendritic Cell-Associated Osteoclastogenesis and Bone Loss
Liu, Y.-C. G., & Teng, Y.-T. A. (2009) · Clinical Reviews in Bone and Mineral Metabolism · doi:10.1007/s12018-009-9059-1 · Cited by 1
The interactions and shared mechanisms of T cells and osteoclasts
Gober, H.-J., & Takayanagi, H. (2009) · Inflammation and Regeneration · doi:10.2492/inflammregen.29.239 · Cited by 1
Effects of endosulfan on human MCF-7 breast cancer cells
Mannon, S. (2011) · e-scholar@UOIT (University of Ontario Institute of Technology) · Cited by 1
Al-thamiree, S. S. M. (2019) · PEARL (University of Plymouth) · doi:10.24382/757 · Cited by 1
Análise econômica do denosumabe e dos bisfosfonatos no tratamento de pacientes com metástase óssea
Matuoka, J. Y. (2019) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.7.2019.tde-23022021-095026 · Cited by 1
Ovarian steroids and cancer: news on the breast, questions on the reproductive tract
Hidalgo‐Mora, J. J., Tarín, J. J., & Cano, A. (2021) · Gynecological Endocrinology · doi:10.1080/09513590.2021.1904871 · Cited by 1
“In a more provocative series of experiments, RANKL has been shown to stimulate the migratory potential of malignant cells in rodents [12].”
BackgroundChevron starts U.S. gulf`s first Lower Cretaceous flow
Petzet, G. A. (1998) · Oil & gas journal/Oil and gas journal · Cited by 1
Beermann, F. (2006) · Drug Discovery Today Disease Models · doi:10.1016/j.ddmod.2006.05.001 · Cited by 1
Metadata
- Authors
- Jones, D. H., Nakashima, T., Sanchez, O. H., Kozieradzki, I., Komarova, S. V., Sarosi, I., Morony, S., Rubin, E., Sarao, R., Hojilla, C. V., Komnenovic, V., Kong, Y.-Y., Schreiber, M., Dixon, S. J., Sims, S. M., Khokha, R., Wada, T., & Penninger, J. M.
- Affiliations
- Institute of Molecular Biotechnology (AT)
- University Health Network (CA)
- McGill University (CA)
- Amgen (United States) (US)
- University of Toronto (CA)
- Pohang University of Science and Technology (KR)
- Medical University of Vienna (AT)
- Western University (CA)
- Corresponding author
- Penninger, Josef M.
- ORCID
- Venue
- Nature
- Published
- 2006-03
- Volume
- 440
- Issue
- 7084
- Pages
- 692-696
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2051255001
- Cited by
- 796
- References
- 22
- Citations by year
- 2026: 10 · 2025: 21 · 2024: 24 · 2023: 32 · 2022: 33 · 2021: 43 · 2020: 43 · 2019: 39 · 2018: 28 · 2017: 43 · 2016: 36 · 2015: 42 · 2014: 45 · 2013: 47 · 2012: 68
- FWCI
- 18.60
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Scholarship@Western (Western University) (submittedVersion)
- Open Access System for Information Sharing (Pohang University of Science and Technology) (submittedVersion)
- Funders
- European Commission
- Oesterreichische Nationalbank
- Canadian Institutes of Health Research
- National Cancer Institute
- Institute of Musculoskeletal Health and Arthritis
- Canadian Arthritis Network
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Mechanisms of cancer metastasis
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
- Keywords
- RANKL, RANK, bone metastasis, tumor cell migration, osteoprotegerin, melanoma, breast cancer, tumor microenvironment, NF-κB signaling
- MeSH terms
- Animals, Bone Neoplasms, Breast Neoplasms, Carrier Proteins, Cell Differentiation, Cell Movement, Epithelial Cells, Female, Humans, Melanoma, Membrane Glycoproteins, Neoplasm Metastasis, Organ Specificity, Paralysis, Signal Transduction, Cell Death, Cell Line, Tumor, Cell Proliferation, Mice, RANK Ligand, Receptor Activator of Nuclear Factor-kappa B
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.